These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 9624465

  • 21. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J, Benfield T, Atzori C, Miller RF.
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [Abstract] [Full Text] [Related]

  • 22. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
    Edge MD, Rimland D.
    AIDS; 1999 May 28; 13(8):991-2. PubMed ID: 10371182
    [No Abstract] [Full Text] [Related]

  • 23. Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.
    James CW, McNelis KC, Szabo S.
    Am J Health Syst Pharm; 2003 Aug 01; 60(15):1572-4. PubMed ID: 12951757
    [No Abstract] [Full Text] [Related]

  • 24. Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation.
    Huang L, Morris AM, Beard CB.
    J Eukaryot Microbiol; 2001 Aug 01; Suppl():180S-181S. PubMed ID: 11906054
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia.
    Kim T, Kim SH, Park KH, Cho OH, Sung H, Kim MN, Choi SH, Jeong JY, Woo JH, Kim YS, Lee SO.
    J Infect Chemother; 2009 Oct 01; 15(5):343-6. PubMed ID: 19856077
    [Abstract] [Full Text] [Related]

  • 27. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH, Ritter J, Müller FM.
    Klin Padiatr; 2001 Sep 01; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [Abstract] [Full Text] [Related]

  • 28. Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis.
    Antinori A, Murri R, Ammassari A.
    AIDS; 1996 Aug 01; 10(9):1046-7. PubMed ID: 8853743
    [No Abstract] [Full Text] [Related]

  • 29. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA.
    Arch Intern Med; 2002 Apr 22; 162(8):921-8. PubMed ID: 11966344
    [Abstract] [Full Text] [Related]

  • 30. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
    Hughes WT.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar 01; 8(3):247-52. PubMed ID: 7859136
    [Abstract] [Full Text] [Related]

  • 31. Drugs for AIDS and associated infections.
    Med Lett Drugs Ther; 1995 Oct 13; 37(959):87-94. PubMed ID: 7565297
    [No Abstract] [Full Text] [Related]

  • 32. Treatment and prophylaxis of Pneumocystis carinii pneumonia.
    Fischl MA.
    AIDS; 1988 Oct 13; 2 Suppl 1():S143-50. PubMed ID: 2976274
    [No Abstract] [Full Text] [Related]

  • 33. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.
    Smith D, Davies S, Nelson M, Youle M, Gleeson J, Gazzard B.
    AIDS; 1990 Oct 13; 4(10):1019-21. PubMed ID: 2261116
    [Abstract] [Full Text] [Related]

  • 34. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
    Cirioni O, Giacometti A, Scalise G.
    J Antimicrob Chemother; 1997 Jan 13; 39(1):45-51. PubMed ID: 9044027
    [Abstract] [Full Text] [Related]

  • 35. [Drugs for pneumocystosis].
    Furet Y, Duong TH, Perrotin D, Breteau M.
    Therapie; 1988 Jan 13; 43(1):33-8. PubMed ID: 3128885
    [No Abstract] [Full Text] [Related]

  • 36. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia.
    Barber BA, Pegram PS, High KP.
    Clin Infect Dis; 1996 Oct 13; 23(4):718-22. PubMed ID: 8909833
    [Abstract] [Full Text] [Related]

  • 37. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
    Hughes WT.
    Antimicrob Agents Chemother; 1988 May 13; 32(5):623-5. PubMed ID: 3260765
    [Abstract] [Full Text] [Related]

  • 38. [Pneumocystis carinii pneumonia in HIV infection. Diagnosis, prognostic factors and curative treatment].
    Saimot AG, Girard PM.
    Presse Med; 1991 Feb 16; 20(6):258-64. PubMed ID: 1672560
    [Abstract] [Full Text] [Related]

  • 39. Atovaquone compared with dapsone to prevent Pneumocystis carinii pneumonia.
    Horowitz HW, Wormser GP.
    N Engl J Med; 1999 May 13; 340(19):1512-3. PubMed ID: 10328722
    [No Abstract] [Full Text] [Related]

  • 40. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
    Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct 01; 19(2):182-8. PubMed ID: 9768629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.